硼替佐米诱发的多发性骨髓瘤患者疼痛性神经病变
Bortezomib-induced painful neuropathy in patients with multiple myeloma.
作者信息
Bilińska Małgorzata, Usnarska-Zubkiewicz Lidia, Pokryszko-Dragan Anna
机构信息
Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
出版信息
Contemp Oncol (Pozn). 2013;17(5):421-6. doi: 10.5114/wo.2013.37214. Epub 2013 Oct 11.
Abstract
Neurotoxicity towards the peripheral nervous system which appears clinically in the form of painful neuropathy is an essential dose-limiting factor during the treatment of multiple myeloma. In this review article different forms of this painful neuropathy are presented together with currently available diagnostic tools which are usually applied to confirm the diagnosis. Also, the most often used neurological scales estimating neurological deficit are presented. Special attention is paid to the management of the reversibility of bortezomib-induced neuropathic pain.
摘要
对周围神经系统的神经毒性在临床上表现为疼痛性神经病变，是多发性骨髓瘤治疗过程中的一个重要剂量限制因素。在这篇综述文章中，介绍了这种疼痛性神经病变的不同形式以及目前用于确诊的可用诊断工具。此外，还介绍了最常用的评估神经功能缺损的神经学量表。特别关注了硼替佐米诱导的神经性疼痛可逆性的管理。
相似文献
1
Bortezomib-induced painful neuropathy in patients with multiple myeloma.
Contemp Oncol (Pozn). 2013;17(5):421-6. doi: 10.5114/wo.2013.37214. Epub 2013 Oct 11.
2
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
PLoS One. 2013 Sep 12;8(9):e72995. doi: 10.1371/journal.pone.0072995. eCollection 2013.
3
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
4
Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Integr Cancer Ther. 2018 Dec;17(4):1115-1124. doi: 10.1177/1534735418803758. Epub 2018 Oct 8.
5
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma.
Arch Med Sci. 2021 Jan 11;18(3):696-703. doi: 10.5114/aoms/114269. eCollection 2022.
6
An Overview of Bortezomib-Induced Neurotoxicity.
Toxics. 2015 Jul 27;3(3):294-303. doi: 10.3390/toxics3030294.
7
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
J Peripher Nerv Syst. 2008 Dec;13(4):267-74. doi: 10.1111/j.1529-8027.2008.00192.x.
8
Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain.
Mol Pain. 2018 Jan-Dec;14:1744806918797042. doi: 10.1177/1744806918797042.
9
Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy.
Mol Pain. 2019 Jan-Dec;15:1744806919850043. doi: 10.1177/1744806919850043.
10
Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S52-S62. doi: 10.1111/jns.12338.
引用本文的文献
1
Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats.
Mol Pain. 2023 Jan-Dec;19:17448069231185694. doi: 10.1177/17448069231185694.
2
Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221114142. doi: 10.1177/15347354221114142.
3
Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients.
Sci Rep. 2022 Jun 16;12(1):10061. doi: 10.1038/s41598-022-13935-2.
4
An Approach to Neurological Disorders in a Kidney Transplant Recipient.
Kidney360. 2020 Jun 16;1(8):837-844. doi: 10.34067/KID.0002052020. eCollection 2020 Aug 27.
5
Supportive care in multiple myeloma: Current practices and advances.
Cancer Treat Res Commun. 2021;29:100476. doi: 10.1016/j.ctarc.2021.100476. Epub 2021 Oct 9.
6
Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.
Exp Neurol. 2021 Feb;336:113519. doi: 10.1016/j.expneurol.2020.113519. Epub 2020 Oct 29.
7
The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419888584. doi: 10.1177/1534735419888584.
8
Neurologic complications of kidney transplantation.
Transl Androl Urol. 2019 Apr;8(2):164-172. doi: 10.21037/tau.2018.08.11.
9
Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Integr Cancer Ther. 2018 Dec;17(4):1115-1124. doi: 10.1177/1534735418803758. Epub 2018 Oct 8.
10
An Overview of Bortezomib-Induced Neurotoxicity.
Toxics. 2015 Jul 27;3(3):294-303. doi: 10.3390/toxics3030294.
本文引用的文献
1
Secondary acute lymphoblastic leukaemia in a multiple myeloma patient.
Contemp Oncol (Pozn). 2012;16(6):593-5. doi: 10.5114/wo.2012.32497. Epub 2013 Jan 4.
2
Characterization of non-length-dependent small-fiber sensory neuropathy.
Muscle Nerve. 2012 Jan;45(1):86-91. doi: 10.1002/mus.22255.
3
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14. doi: 10.4065/mcp.2009.0649.
4
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
Eur J Cancer. 2010 Feb;46(3):479-94. doi: 10.1016/j.ejca.2009.12.008. Epub 2010 Jan 4.
5
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Eur J Pain. 2010 Apr;14(4):343-50. doi: 10.1016/j.ejpain.2009.07.001. Epub 2009 Aug 19.
6
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Leuk Res. 2010 Apr;34(4):471-4. doi: 10.1016/j.leukres.2009.07.022. Epub 2009 Aug 11.
7
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.
8
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
J Peripher Nerv Syst. 2008 Dec;13(4):267-74. doi: 10.1111/j.1529-8027.2008.00192.x.
9
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.
10
Immune-mediated neuropathies in myeloma patients treated with bortezomib.
Clin Neurophysiol. 2008 Nov;119(11):2507-12. doi: 10.1016/j.clinph.2008.08.007. Epub 2008 Oct 1.
Zotero 插件